NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Gynaecology: Cervix — adjuvant therapy after radical hysterectomy

Free question published 01 November 2026

GynaecologyCervix — adjuvant therapy after radical hysterectomy

A 41-year-old woman underwent radical hysterectomy and pelvic lymphadenectomy for an apparent early cervical cancer. Final pathology unexpectedly shows two positive pelvic lymph nodes and microscopic parametrial involvement, with clear vaginal margins. Performance status is 0 and renal function is normal. What adjuvant treatment is most appropriate?

  1. AConcurrent cisplatin-based chemoradiotherapy
  2. BObservation with close surveillance
  3. CAdjuvant carboplatin and paclitaxel chemotherapy alone
  4. DPelvic radiotherapy alone
  5. EVaginal brachytherapy alone

Why A is correct

Positive pelvic nodes, parametrial involvement and positive surgical margins are the Peters high-risk factors. The Peters trial showed that adjuvant concurrent cisplatin-based chemoradiotherapy improves overall and disease-free survival compared with radiotherapy alone in this group, so concurrent chemoradiotherapy is the standard.

And why the others are not

  • BIncorrect. High-risk pathology (positive nodes plus parametrial invasion) carries a 25-40% recurrence risk; observation is inadequate.
  • CIncorrect. Chemotherapy alone without radiotherapy is not the standard adjuvant approach for these high-risk pathological features.
  • DIncorrect. Radiotherapy alone is inferior to concurrent chemoradiotherapy in patients with Peters high-risk factors.
  • EIncorrect. Vaginal brachytherapy alone does not address nodal and parametrial disease.

Source Adjuvant chemoradiotherapy after radical hysterectomy for high-risk cervical cancer (Peters et al) — Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology, 2000.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing